Cargando…

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review

Pimavanserin was approved for treating Parkinson’s disease (PD) psychosis, based upon 21 completed studies. This review article is to understand PD psychosis and assess the efficacy and safety of pimavanserin. A literature search was carried out using the keyword “pimavanserin” and cross-referencing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Rikinkumar S, Bhela, Jatminderpal, Tahir, Muhammad, Pisati, Sindhu Reddy, Hossain, Sadaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760879/ https://www.ncbi.nlm.nih.gov/pubmed/31572642 http://dx.doi.org/10.7759/cureus.5257

Ejemplares similares

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Comorbid Depression and Psychosis in Parkinson’s Disease: A Report of 62,783 Hospitalizations in the United States
por: Imran, Sundus, et al.
Publicado: (2019)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

The Opioid Epidemic and Primary Headache Disorders: A Nationwide Population-Based Study
por: Patel, Urvish K, et al.
Publicado: (2020)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin Use in Lewy Body Dementia: A Case Report Demonstrating the Medication’s Efficacy
por: Baker, Michelle, et al.
Publicado: (2023)

Pros and Cons of Marijuana in Treatment of Parkinson’s Disease
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Significant potential of melatonin therapy in Parkinson’s disease – a meta-analysis of randomized controlled trials
por: Iftikhar, Sadaf, et al.
Publicado: (2023)

Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis
por: Mantri, Sneha, et al.
Publicado: (2021)

Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Parkinson's Disease in Pregnancy: A Case Report and Review of the Literature
por: Olivola, Sara, et al.
Publicado: (2020)

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020)

Patient Satisfaction in Surgery for Parkinson’s Disease: A Systematic Review of the Literature
por: Elsayed, Galal A, et al.
Publicado: (2019)

The protective effects of Pimavanserin against cerebral ischemia-induced brain injury
por: Li, Xiang, et al.
Publicado: (2021)

A Physical Rehabilitation Approach for Parkinson’s Disease: A Systematic Literature Review
por: Tobar, Andrea, et al.
Publicado: (2023)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Delusional Infestation Secondary to the Dopamine Agonist Ropirinole in a Patient With Parkinson's Disease: A Case Report With an Outline of the Biology of Psychosis
por: Kesserwani, Hassan
Publicado: (2021)

Tension Pneumocephalus From an Eroding Cholesteatoma: A Case Report and Review of the Literature
por: Khan, Muhammad Z, et al.
Publicado: (2021)

Diagnostic Dilemma and Management Difficulties in a Young Patient With Psychosis and Benign Chorea: A Case Report and Review of the Literature
por: Meza-Venegas, Joyce, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tpjo4oafr9uivug29si7piravs